Information Provided By:
Fly News Breaks for April 20, 2016
BMRN
Apr 20, 2016 | 12:55 EDT
Piper Jaffray analyst Joshua Schimmer calls BioMarin's hemophilia data "very surprising" as he was not expecting to see expression levels get to around 60% of normal, which was achieved in the first two patients in the high dose cohort. Some patients reached near-normal cure levels, which could disrupt the entire hemophilia A treatment paradigm, Schimmer tells investors in a research note. Further, BioMarin's Batten's data appears to support approval while achondroplasia data continue to show "improved growth velocity," the analyst writes. He has an Overweight rating on the shares with a $107 price target.
News For BMRN From the Last 2 Days
There are no results for your query BMRN